Fennec Pharmaceuticals Inc. (TSE:FRX - Get Free Report) Director Rostislav Christov Raykov sold 10,000 shares of the firm's stock in a transaction that occurred on Thursday, July 3rd. The shares were sold at an average price of C$11.71, for a total value of C$117,096.00.
Rostislav Christov Raykov also recently made the following trade(s):
- On Thursday, June 5th, Rostislav Christov Raykov sold 10,000 shares of Fennec Pharmaceuticals stock. The stock was sold at an average price of C$10.66, for a total value of C$106,586.00.
- On Friday, May 16th, Rostislav Christov Raykov sold 16,667 shares of Fennec Pharmaceuticals stock. The stock was sold at an average price of C$9.49, for a total value of C$158,203.16.
Fennec Pharmaceuticals Price Performance
FRX stock traded up C$0.27 during midday trading on Friday, hitting C$12.16. 1,210 shares of the stock were exchanged, compared to its average volume of 1,139. The stock's 50-day moving average price is C$10.37 and its 200-day moving average price is C$9.32. The stock has a market cap of C$234.50 million, a price-to-earnings ratio of -205.99 and a beta of 0.25. Fennec Pharmaceuticals Inc. has a fifty-two week low of C$5.65 and a fifty-two week high of C$12.16. The company has a debt-to-equity ratio of -620.83, a quick ratio of 10.17 and a current ratio of 7.80.
Fennec Pharmaceuticals Company Profile
(
Get Free Report)
Fennec Pharmaceuticals Inc is a clinical-stage biotechnology company. It is primarily engaged in research and development activities. The company is developing Sodium Thiosulfate (STS), a chemo-protectant against hearing loss associated with platinum-based chemotherapy. Its lead product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin induced hearing loss, or ototoxicity in children.
Featured Articles
Before you consider Fennec Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Fennec Pharmaceuticals wasn't on the list.
While Fennec Pharmaceuticals currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
